期刊文献+

自身免疫性甲状腺疾病治疗中应用糖皮质激素的效果 被引量:1

Clinical effect of glucocorticoid in the treatment of autoimmune thyroid disease
下载PDF
导出
摘要 目的 分析在自身免疫性甲状腺疾病治疗中应用糖皮质激素的效果.方法 选择2014年10月至2016年10月来我院治疗的自身免疫性甲状腺疾病患者92例作为研究对象,按照随机分组的方法将92例患者分为观察组、对照组,每组46例.对照组行常规治疗,观察组在此基础上给予糖皮质激素治疗.比对两组患者甲状腺肿体积、甲状腺功能指标以及不良反应发生情况.结果 治疗后,观察组甲状腺肿体积均小于对照组,且甲状腺功能指标更优、不良反应发生率更低,组间比较,差异具有统计学意义(P<0.05).结论 将糖皮质激素应用于自身免疫性甲状腺疾病治疗中,可有效减小患者甲状腺肿体积,改善患者的甲状腺功能,提升患者的整体治疗效果. Objective To analyze the effect of glucocorticoid in the treatment of autoimmune thyroid disease. Methods Ninety-two cases of patients with autoimmune thyroid disease who were treated in our hospital from October 2014 to October 2016 were selected as the research objects. The patients were divided into observation group and control group according to the method of randomization, with 46 cases in each group. Patients in the control group were treated with conventional thera- py, and patients in the observation group were treated with glucocorticoid based on conventional therapy. Goiter volume, thy- roid function indicators and adverse reactions of the two groups were compared. Results After treatment, the volume of goiter of the observation group was smaller than that of the control group, and the thyroid function was better, adverse reactions was less than that of the control group, the differences were statistically significant (P〈0.05). Conclusion Glucocorticoid can be used in the treatment of autoimmune thyroid disease, which can effectively reduce the volume of goiter, improve the thyroid function and overall therapeutic effect of patients.
作者 王前
出处 《临床研究》 2017年第6期91-92,共2页 Clinical Research
关键词 自身免疫性甲状腺疾病 糖皮质激素 甲状腺体积 autoimmune thyroid disease glucocorticoid goiter volame
  • 相关文献

参考文献4

二级参考文献40

  • 1何文广.地奥司明治疗甲状腺术后切口水肿的效果[J].求医问药(下半月),2013(12):294-295. 被引量:4
  • 2王彤,王永和.甲状腺术后颈部软组织异常肿胀二例.实用外科杂志,1998,8(8):416.
  • 3Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives[J]. Endocr Rev, 2000,21(2):168-199.
  • 4Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy(EUGOGO) on management of GO[J]. Eur J Endocrinol, 2008,158(3):273-285.
  • 5Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity[J]. J Clin Endocrinol Metab, 2011,96(2):320-332.
  • 6Bahn R. High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now?[J] Thyroid, 2012,22(1):1-2.
  • 7Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves' orbitopathy(EUGOGO) on management of Graves' orbitopathy[J]. Thyroid, 2008,18(3):333-346.
  • 8Mourits MP, van Kempen-Harteveld ML. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study[J]. Lancet, 2000,355(9214):1505-1509.
  • 9Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 2004,89(1):15-20.
  • 10Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2008,115(2):398-409.

共引文献38

同被引文献25

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部